Participated · Series B · Aug 2026

Founded in 2014, Farmbot builds satellite-connected sensors and a software platform that lets farmers monitor tanks, troughs, dams, pumps and rainfall remotely. The company serves more than 12,000 customers across Australia, North America and other markets and reports management of about 10 million cattle and 15 million sheep. It operates as Ranchbot in the U.S. and is now headquartered in Fort Worth, Texas. With the recent $22 million Series B, Farmbot plans a corporate reorganization to establish Ranchbot Technology Holdings Inc. as the global parent, hire additional staff, and continue improving its hardware and software. Leadership has indicated plans to evolve the product offering into broader agricultural and water management solutions for the farm sector.

Participated · Series D · Sep 2025

Enveda is a clinical-stage biotechnology company that learns from life’s chemistry to create small-molecule therapeutics using AI-powered metabolomics and a proprietary chemical sequencer. The platform makes previously inaccessible natural chemistry searchable and uses automation to map therapeutic properties at high throughput. Enveda says it delivers 12+ development candidates 4× faster and 10× cheaper than industry averages and has built one of the world’s largest collections of natural samples. Its pipeline includes sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program. ENV-294, the lead program, is a first-in-class oral anti-inflammatory small molecule discovered on the platform and has moved into a Phase 1b trial after favorable Phase 1a results; Enveda has enrolled the first patient. The company recently raised additional capital and added industry veteran Dr. Mikael Dolsten to its board to support clinical advancement across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and other indications. Enveda harnesses AI-powered tools to identify and characterize molecules produced by living organisms, building a database of chemical biodiversity it calls the library of life. Its platform integrates computational methods with deep chemical and biological insights to uncover novel mechanisms of action and drug candidates. The company has advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, into clinical trials and highlights the potential for a safe, effective oral therapy in immunology and inflammation. Enveda plans to expand its clinical pipeline in 2025 and further enhance its AI-driven discovery capabilities. The company frames its approach as metabolite-driven drug development aimed at delivering medicines faster by learning from evolved solutions in nature. Enveda is a biotechnology company that uses an AI-powered platform combining metabolomics, machine learning, and automated high-throughput laboratory workflows to translate natural compounds into drug candidates. Its platform has characterized the structure and function of over 1 million natural compounds, creating the largest known natural product dataset custom-built for modern drug discovery. The company says this approach answers what molecules are and what they do at scale and enables discovery roughly four times faster than historical averages. Enveda’s pipeline includes 10 Development Candidates across immunology & inflammation, obesity, fibrosis, and neurosensory indications. The company recently received IND clearance for ENV-294, which entered Phase I at the end of October. The new funding will support multiple clinical catalysts in 2025 and 2026 and further investment in the platform and discovery programs. Enveda Biosciences, founded in 2019 and based in Boulder, Colorado, combines AI with ethnobotanical knowledge to identify medicinal molecules from plants. The company has assembled a database of about 38,000 medicinal plants linked to roughly 12,000 diseases and symptoms. Using a transformer model that deciphers the "chemical language" of whole samples, Enveda prioritizes sets of molecules for development rather than studying single compounds in isolation. That platform has produced near-term assets: two drugs (one for skin conditions including eczema, and one for inflammatory bowel diseases) are expected to enter clinical trials later this year. Financially, the company has raised capital that totals $230 million to date and plans to pursue a Series C after the start of those clinical trials. Enveda builds a proprietary platform that combines large language models, metabolomics, and robotics to create a high-resolution chemical map of nature and search nature’s chemical space for drug discovery. The platform addresses long-standing obstacles in natural product drug development, including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. Enveda pairs this technology with experienced drug hunters and data scientists to advance platform-derived molecules. The company plans to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications. Financially, Enveda has been raising growth capital to advance its pipeline and platform and recently completed additional financing to support clinical progress. For more information, Enveda directs readers to envedabio.com.

Participated · Series A · Sep 2024

Quantum Source develops a photonic quantum architecture aimed at building fault-tolerant, practical quantum computers. Its approach targets scalability to millions of qubits while reducing complexity, footprint, power consumption, and cost versus other implementations. The company intends to use recent funding to enhance engineering capabilities and accelerate commercialization of quantum solutions. Founded in 2021 by Oded Melamed, Gil Semo, Dan Charash, and Professor Barak Dayan, the company is based in Ness Ziona, Israel. Quantum Source has 45 employees, more than half of whom hold PhDs, reflecting a highly technical team. Recent financing brought total capital raised to $77M (including a $50M Series A), providing capital to support product development and commercialization. Quantum Source, founded in 2021 and based in Rehovot, Israel, is developing technology to enable commercially viable photonic quantum computers that can scale to millions of qubits. The company uses a unique approach for generating photons and quantum gates that it says is five orders of magnitude more efficient than state-of-the-art implementations. QS targets fault tolerance and large-scale scalability to unlock applications in drug design, materials development, cybersecurity, and AI data processing. The team includes four co-founders with semiconductor and physics backgrounds and a broader technical staff with 18 PhDs and extensive publication records. The company plans to expand its research and development team as it scales to reach significant technical and performance milestones. Its leadership has prior experience founding, scaling, and exiting companies to Apple, Broadcom, and Sony. Quantum Source is developing breakthrough photonic technology to enable commercially viable quantum computers with millions of qubits. The company says its approach targets the scalability limits of current matter-based systems and aims to unlock applications in drug and materials discovery, finance, and cybersecurity. Quantum Source emerged from stealth with a $15 million seed round to advance product development and commercialization. The founding team includes three serial entrepreneurs and Prof. Barak Dayan of the Weizmann Institute of Science, and the company employs twenty-five physicists and engineers, fifteen of whom hold PhDs. Quantum Source was established in 2021 and is based in Rehovot, Israel.